Health Care and Pharma | Research Reports, News, Events, Research on Demand

Research Reports Titles

  • Global and China Dental Floss Research Report to 2020

    This report focuses on the current state of the Camel Farming and Dairy Production. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. Divided into two camel species, Dromedary and Bactrian, the report discusses camel distribution, current breeding strategies, and new technologies by regions. Camel dairy products, like camel milk powder, camel milk ice cream, are introduced by regions. The Farming cost and duration are also discussed by regions. The Camel Dairy market analyses are provided for the global markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans are also discussed and manufacturing processes and cost structures analyzed. Camel Dairy industry import export, consumption, supply and demand, cost price and production value gross margins are also provided. The report focuses on global major leading camel dairy producers providing information such as company profiles, product picture and specification, capacity production, price, cost, production value and contact information. The Camel industry development trends and marketing channels are analyzed. Finally the feasibility of new investment projects are assessed. Last, a comprehensive conclusion are provided.

    • Release Date: June 14, 2016
    • Price: USD 2650
    • Format: PDF

  • Dry Eye Syndrome - US Drug Forecast and Market Analysis to 2024

    S), also known as keratoconjunctivitis sicca, is a multifactorial disease of the tears and ocular surface. This ocular condition can cause ocular discomfort, visual disturbances, and tear film instability, which can potentially damage the ocular surface. The DES market has had few new therapeutics in the last decade with Japan seeing the most change in this time with the arrival of Diquas and Mucosta in 2010 and 2013, respectively. However, the lack of treatment options is about to change with the expected launch of numerous pipeline DES drugs during the forecast period, which will be a significant driver of growth in the 9MM. Indeed, this change has already been initiated with Ikervis recent arrival in Europe in 2015. Furthermore, additional marketing approvals are being sought for currently marketed DES drugs, Restasis and Diquas, in new countries in the 9MM, which will provide a source of growth in this market. GlobalData estimates that DES drug sales in the US reached $1.3 billion during 2014, making it the largest market within the 9MM. After an initial period of minimal growth, GlobalData estimates that the DES market will undergo a period of steady growth from 2016 and beyond, but this growth will begin to wane slightly towards the end of the forecast period. This growth is mainly attributed to the expected introduction of the highly anticipated pipeline DES drug, lifitegrast in late 2016, and additional pipeline products in 2018. This expansion of treatment options for DES patients will have the added effect of increasing overall treatment rates in the US. *This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase. Scope - Overview of DES including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for the top drugs in the US from 2014-2024. - Analysis of the impact of key events as well the drivers and restraints affecting the US DES market. Reasons to buy - Understand and capitalize by identifying products that are most likely to ensure a robust return - Stay ahead of the competition by understanding the changing competitive landscape for DES. - Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential - Make more informed business decisions from insightful and in-depth analysis of drug performance - Obtain sales forecast for drugs from 2014-2024 in US.

    • Release Date: November 05, 2015
    • Price: USD 4995
    • Format: PDF

  • Dry Eye Syndrome - Japan Drug Forecast and Market Analysis to 2024

    Dry Eye Syndrome - Japan Drug Forecast and Market Analysis to 2024 Summary Dry Eye Syndrome (DES), also known as keratoconjunctivitis sicca, is a multifactorial disease of the tears and ocular surface. This ocular condition can cause ocular discomfort, visual disturbances, and tear film instability, which can potentially damage the ocular surface. The DES market has had few new therapeutics in the last decade with Japan seeing the most change in this time with the arrival of Diquas and Mucosta in 2010 and 2013, respectively. However, the lack of treatment options is about to change with the expected launch of numerous pipeline DES drugs during the forecast period, which will be a significant driver of growth in the 9MM. Indeed, this change has already been initiated with Ikervis recent arrival in Europe in 2015. Furthermore, additional marketing approvals are being sought for currently marketed DES drugs, Restasis and Diquas, in new countries in the 9MM, which will provide a source of growth in this market. GlobalData estimated that DES drug sales in Japan during 2014 reached $360.6m, making it the second largest market in the 9MM. GlobalData estimates that the DES market will follow a moderate steady growth trend throughout the forecast period. GlobalData expects Santen s Hyalein, a sodium hyaluronate-based artificial tears product, to retain its position as the top selling DES eye prescription drug in Japan over the forecast period, generating estimated sales of $227.6m in 2024. *This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase. Scope - Overview of DES including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for the top drugs in Japan from 2014-2024. - Analysis of the impact of key events as well the drivers and restraints affecting Japan DES market. Reasons to buy - Understand and capitalize by identifying products that are most likely to ensure a robust return - Stay ahead of the competition by understanding the changing competitive landscape for DES. - Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential - Make more informed business decisions from insightful and in-depth analysis of drug performance - Obtain sales forecast for drugs from 2014-2024 in Japan.

    • Release Date: November 05, 2015
    • Price: USD 4995
    • Format: PDF

  • Dry Eye Syndrome - China Drug Forecast and Market Analysis to 2024

    Dry Eye Syndrome - China Drug Forecast and Market Analysis to 2024 Summary Dry Eye Syndrome (DES), also known as keratoconjunctivitis sicca, is a multifactorial disease of the tears and ocular surface. This ocular condition can cause ocular discomfort, visual disturbances, and tear film instability, which can potentially damage the ocular surface. The DES market has had few new therapeutics in the last decade with Japan seeing the most change in this time with the arrival of Diquas and Mucosta in 2010 and 2013, respectively. However, the lack of treatment options is about to change with the expected launch of numerous pipeline DES drugs during the forecast period, which will be a significant driver of growth in the 9MM. Indeed, this change has already been initiated with Ikervis recent arrival in Europe in 2015. Furthermore, additional marketing approvals are being sought for currently marketed DES drugs, Restasis and Diquas, in new countries in the 9MM, which will provide a source of growth in this market. The value of the Chinese DES market is expected to rise over the forecast period at a CAGR of 10.4%. In 2018, the size of the DES market in China is anticipated to exceed that of the Indian market, and will become the third largest single market from that point forward. GlobalData expects Santen s Hialid, a sodium hyaluronate-based artificial tears product, to retain its position as the top-selling DES eye prescription drug in China over the forecast period, generating drug sales of $138.5m in 2024. *This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase. Scope - Overview of DES including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on the key drugs in China including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for the top drugs in China from 2014-2024. - Analysis of the impact of key events as well the drivers and restraints affecting China DES market. Reasons to buy - Understand and capitalize by identifying products that are most likely to ensure a robust return - Stay ahead of the competition by understanding the changing competitive landscape for DES. - Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential - Make more informed business decisions from insightful and in-depth analysis of drug performance - Obtain sales forecast for drugs from 2014-2024 in China.

    • Release Date: November 05, 2015
    • Price: USD 4995
    • Format: PDF

  • Dry Eye Syndrome - India Drug Forecast and Market Analysis to 2024

    Dry Eye Syndrome - India Drug Forecast and Market Analysis to 2024 Summary Dry Eye Syndrome (DES), also known as keratoconjunctivitis sicca, is a multifactorial disease of the tears and ocular surface. This ocular condition can cause ocular discomfort, visual disturbances, and tear film instability, which can potentially damage the ocular surface. The DES market has had few new therapeutics in the last decade with Japan seeing the most change in this time with the arrival of Diquas and Mucosta in 2010 and 2013, respectively. However, the lack of treatment options is about to change with the expected launch of numerous pipeline DES drugs during the forecast period, which will be a significant driver of growth in the 9MM. Indeed, this change has already been initiated with Ikervis recent arrival in Europe in 2015. Furthermore, additional marketing approvals are being sought for currently marketed DES drugs, Restasis and Diquas, in new countries in the 9MM, which will provide a source of growth in this market. Diagnosis and treatment rates are expected to increase slightly for all severities of DES in India over the course of the forecast period. This rise in treatment is mainly due to improving disease awareness among both physicians and patients, which will be the main source of growth in this otherwise stagnant market. Allergan s Restasis is the only approved prescription DES drug in the Indian dry eye market, and was the leading drug (ahead of artificial tears products) in 2014. *This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase. Scope - Overview of DES including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on the key drugs in India including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for the top drugs in India from 2014-2024. - Analysis of the impact of key events as well the drivers and restraints affecting India DES market. Reasons to buy - Understand and capitalize by identifying products that are most likely to ensure a robust return - Stay ahead of the competition by understanding the changing competitive landscape for DES. - Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential - Make more informed business decisions from insightful and in-depth analysis of drug performance - Obtain sales forecast for drugs from 2014-2024 in India.

    • Release Date: November 05, 2015
    • Price: USD 4995
    • Format: PDF

  • Dry Eye Syndrome - 5EU Drug Forecast and Market Analysis to 2024

    Dry Eye Syndrome - 5EU Drug Forecast and Market Analysis to 2024 Summary Dry Eye Syndrome (DES), also known as keratoconjunctivitis sicca, is a multifactorial disease of the tears and ocular surface. This ocular condition can cause ocular discomfort, visual disturbances, and tear film instability, which can potentially damage the ocular surface. The DES market has had few new therapeutics in the last decade with Japan seeing the most change in this time with the arrival of Diquas and Mucosta in 2010 and 2013, respectively. However, the lack of treatment options is about to change with the expected launch of numerous pipeline DES drugs during the forecast period, which will be a significant driver of growth in the 9MM. Indeed, this change has already been initiated with Ikervis recent arrival in Europe in 2015. Furthermore, additional marketing approvals are being sought for currently marketed DES drugs, Restasis and Diquas, in new countries in the 9MM, which will provide a source of growth in this market. GlobalData estimated that DES drug sales in the 5EU reached $181m during the base year of 2014. The launch of Santen s new DES drug, Ikervis, in 2015 will be the main driver for this significant growth in these markets. The expected arrival of pharmacotherapies into the DES market in the 5EU during the forecast period will cause the relative market share of these artificial tears products to drastically fall to 36.9% by 2024. *This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase. Scope - Overview of DES including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on the key drugs in 5EU including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for the top drugs in 5EU from 2014-2024. - Analysis of the impact of key events as well the drivers and restraints affecting 5EU DES market. Reasons to buy - Understand and capitalize by identifying products that are most likely to ensure a robust return - Stay ahead of the competition by understanding the changing competitive landscape for DES. - Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential - Make more informed business decisions from insightful and in-depth analysis of drug performance - Obtain sales forecast for drugs from 2014-2024 in 5EU.

    • Release Date: November 05, 2015
    • Price: USD 6995
    • Format: PDF

  • Dry Eye Syndrome - Current and Future Players

    uture Players Summary GlobalData has released its pharma report,  Dry Eye Syndrome - Current and Future Players . The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Dry Eye Syndrome Market. The report identifies and analyses the key companies shaping and driving the global Dry Eye Syndrome market. The report provides insight into the competitive Dry Eye Syndrome landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData s team of industry experts. *This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase. Scope - Investigation of current and future market competition for Dry Eye Syndrome - Competitor assessment - Coverage of key market players and company profiles including business description, financial overview and SWOT analysis. - Strategic assessment of Dry Eye Syndrome sector through market impact analysis, future market scenario and company analysis Reasons to buy - Gain a high level view of the trends shaping and driving Dry Eye Syndrome market - Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition. - Create an effective counter-strategy to gain a competitive advantage against those currently in the market - What s the next big thing in the global Dry Eye Syndrome market landscape? Identify, understand and capitalize

    • Release Date: November 05, 2015
    • Price: USD 2995
    • Format: PDF


Create Account



Log In Your Account